Diisopropylamine Dichloroacetate (DADA): Research, Dosing, and Where to Buy in 2026
A research-first profile for Diisopropylamine Dichloroacetate (DADA) (isopropylene dloracetate, dasopropamine dchloroacetate, data, DCA), aggregating mechanism notes, transcript dosing mentions, vendor recommendations, and PubMed-indexed literature without presenting medical guidance.
We were unable to verify the underlying compound, mechanism, or peer-reviewed evidence for Diisopropylamine Dichloroacetate (DADA). It may be a branded blend, a research-stage compound with thin literature, or a name without a single canonical formulation. Do not assume safety based on this page existing. Independently verify what the product actually contains, talk to a qualified clinician, and check current regulatory status before any consumption decision. We list it educationally so that curiosity doesn't lead someone to unverified sources.
Diisopropylamine Dichloroacetate (DADA) is a research compound profiled here from named-expert transcripts and peer-reviewed literature, without medical guidance. As of July 2026, The Peptide Wiki aggregates 8 PubMed-cited papers, and 2 transcript dosing protocols for Diisopropylamine Dichloroacetate (DADA), each linked to its source.
- Also indexed as isopropylene dloracetate, dasopropamine dchloroacetate, data, DCA.
- 2 aggregated dosing-protocol mentions from source transcripts.
- 8 PubMed-indexed citations listed in the research table below.
- 0 vendor recommendations captured from named experts.
What is Diisopropylamine Dichloroacetate (DADA)?
Research compound aggregated from creator and literature mentions. No direct disease-treatment claims are made on this page.
Diisopropylamine Dichloroacetate (DADA) Dosing Protocols
The entries below are transcript-derived dosing mentions. They are preserved for research context and are not medical advice.
| Speaker | Source | Timestamp | Protocol | Evidence |
|---|---|---|---|---|
| VigorousClips | This Is What MMA Fighters Take And Try To Hide | Stamina, Endurance,... | 00:04:50 | The host reported using 25 to 100 mg intramuscularly 30 to 60 minutes pre-sparring or pre-match, with a maximum frequency of 1 to 3 times weekly. According to the protocol discussed, this approach would be stacked with Mildronate and a high carbohydrate diet to support ATP-recycling. The reported cycling involved alternating 3 weeks on / 3 weeks off alongside Mildronate, switching to a Cardarine/Carnitine/AICAR combination during off weeks. The host noted the importance of monitoring blood pressure due to reported vasodilatory effects. | anecdotal |
| VigorousClips | These Fat Burners Won't Give You A Heart Attack, Non-Stimulant... | 00:08:14 | Reported use as injectable pre-workout for perceived energy/stamina benefits during workouts (no reported fat-loss effect, unlike AICAR) | anecdotal |
Where to Buy Diisopropylamine Dichloroacetate (DADA) in 2026
No tracked vendor recommendations for Diisopropylamine Dichloroacetate (DADA) yet. See our vendor directory.
Side Effects and Safety
Anecdotal reports and study-level observations vary by route, dose, and individual. This page does not provide medical advice. Consult a qualified clinician before any research use.
User Reviews
User reviews aggregator coming Q3 2026 (Reddit + YouTube comments + Discord research notes). Until then, see the expert quote section above and PubMed citations below.
Research Efficacy Snapshot
Published efficacy percentages cited in PubMed trials and named-expert reports about Diisopropylamine Dichloroacetate (DADA). Each line links to the original source.
- "In the animal model, combined treatment with 100 mg/kg DADA and 40 mg/kg FZ resulted in a 50% reduction in complete tumor regression, compared to 11.1% and 0% in the single-agent treatment groups, respectively." · Nguyen T et al, 2025 PubMed
- "No case dropped out in the trial but four cases were eliminated (4/127, 3.1%)." · Lu L et al, 2005 PubMed
- "After 8 weeks of treatment, the overall improvement of clinical symptoms in the high dosage and in the low dosage group was 87.8% and 79.6%, respectively." · Lu L et al, 2005 PubMed
- "ALT normalization was found in 55.7% and 69.4% of the cases in the two groups, serum lipids were lowered in 67.2% and 67.7% and ultrasound grading of the liver alteration severity was lowered in 51.7% and 43.5% in the two groups." · Lu L et al, 2005 PubMed
- "One case from each group was found having an adverse drug reaction of dryness of the mouth (1.6%)." · Lu L et al, 2005 PubMed
Research and Studies
8 PubMed-indexed papers reference Diisopropylamine Dichloroacetate (DADA). Top 8 shown.
Legal Status
Diisopropylamine Dichloroacetate (DADA) is presented here as a research compound. FDA approval status, scheduling, WADA status, and state-specific telehealth rules may apply. Always verify current regulatory status. Last verified: 2026-07-09.
Frequently Asked Questions
Is Diisopropylamine Dichloroacetate (DADA) FDA-approved?
Diisopropylamine Dichloroacetate (DADA) is presented on this page as a research compound. FDA approval status, scheduling, and state-specific rules may apply and change. Verify current regulatory status before any decision.
What dosing is reported for Diisopropylamine Dichloroacetate (DADA)?
This page aggregates 2 dosing-protocol mention(s) from named-expert transcripts, each linked to a verbatim source timestamp. See the Dosing Protocols table above. Mentions are anecdotal, not medical advice.
How much research has been published on Diisopropylamine Dichloroacetate (DADA)?
8 PubMed-indexed paper(s) reference Diisopropylamine Dichloroacetate (DADA) in our current research feed. See the Research and Studies section above for citations.